Dec 13, 2012 by Brandy Betz1 Catalyst Biotech Investors Need to WatchPhase 3 trial results could make or break these companies.
Dec 11, 2012 by Brandy BetzReport: $700,000 of Gold Dust Missing From Pfizer LabAuthorities are investigating the case in Missouri.
Dec 5, 2012 by Brandy Betz3 Things to Watch at Lexicon A small-cap poised for breakthrough with two phase 3 drugs.
Dec 5, 2012 by Brandy Betz3 Things to Watch at NPS Pharmaceuticals A niche driven small-cap boasts surprising fundamentals.
Nov 29, 2012 by Brandy BetzThis Drug Helps Investors Rest Easy Merck's new drug aims to revamp insomnia treatments.
Nov 27, 2012 by Brandy Betz3 Things to Watch at ExelixisExelixis is poised for FDA approval -- but there's more to come.
Nov 21, 2012 by Brandy BetzBig Pharma's Safest Diabetes PlayThree companies bet on a well-established class of diabetes treatments. Who will win?
Nov 19, 2012 by Brandy Betz3 Things to Watch With Nektar TherapeuticsWas Nektar's crash a short-term stumble or a portent?
Nov 16, 2012 by Brandy BetzThis Top-Dollar Drug Hits the Discount RackAre price slashes for expensive meds the way of the future?
Nov 14, 2012 by Brandy BetzWho Will Pioneer the New Diabetes Market? A new class of innovative treatments is ready for a victor.
Nov 13, 2012 by Brandy BetzIs This Diabetes Drug Merck's Next Blockbuster?Does Merck have a best-seller on its hands?
Nov 13, 2012 by Brandy BetzCan Ariad Survive on 2 Drugs? Will two leukemia treatments carry Ariad to success?
Nov 8, 2012 by Brandy BetzDoes Amarin Need the FDA to Play NCE?How important is it for Amarin to be declared a new chemical entity?
Nov 6, 2012 by Brandy Betz5 Companies Dominating DiabetesAn overview of diabetes and the big pharma players at the top of the game.
Nov 5, 2012 by Brandy Betz3 Things to Watch With BioMarin BioMarin's share price skyrocketed today - but what should investors be watching for the long term?
Nov 5, 2012 by Brandy BetzArena's Pipeline Problems Arena may have a hit with Belviq, but what comes next?
Nov 2, 2012 by Brandy Betz3 Things to Watch With Seattle GeneticsAn innovative technology is the fuel behind Seattle Genetics' growth potential.
Nov 1, 2012 by Brandy Betz3 Things to Watch With Sarepta TherapeuticsSarepta Therapeutics could have a big year if its lead drug gets the fast track.
